ARTICLE | Tools & Techniques
Removing immunotoxin immunogenicity
April 14, 2011 7:00 AM UTC
Researchers at the National Cancer Institute have developed an approach to decrease the immunogenicity of therapeutic proteins that involves identifying and removing immunogenic B cell epitopes.1 As proof of concept, the group applied its method to MedImmune LLC's moxetumomab pasudotox
and engineered an analog that was nonimmunogenic in mice...